Cargando…

Efficacy of PEGylated Interferon in Treatment-Experienced Chinese Patients With HBeAg Positive Chronic Hepatitis B

BACKGROUND: After treatment cessation, a high prevalence of relapse was reported in chronic hepatitis B (CHB) patients in China, especially in nucleot(s)ide analogues (NUCs)-experienced patients. Re-treatment for these patients remains unsolved. OBJECTIVES: This study aims to evaluate the efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiong, Yue-Li, Li, Hu, Liu, Fen, Zhang, Dazhi, Ren, Hong, Hu, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2016
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888231/ https://www.ncbi.nlm.nih.gov/pubmed/27257427 http://dx.doi.org/10.5812/hepatmon.35357

Ejemplares similares

The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B
por: He, Yi, et al.
Publicado: (2022)

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients
por: Keshvari, Maryam, et al.
Publicado: (2015)

Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B
por: Li, Hu, et al.
Publicado: (2018)

A Missense Variant in Granulysin is Associated with the Efficacy of Pegylated-Interferon-Alpha Therapy in Chinese Patients with HBeAg-Positive Chronic Hepatitis B
por: Li, Jing, et al.
Publicado: (2021)

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients
por: Yang, Jiezuan, et al.
Publicado: (2014)

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b
por: Ma, Hui, et al.
Publicado: (2016)

CD55 Variant Associated with Pegylated-interferon α Therapy Response in HBeAg-positive Chronic Hepatitis B Patients
por: Chen, Jiaxuan, et al.
Publicado: (2023)

Differential Plasma MicroRNA Profiles in HBeAg Positive and HBeAg Negative Children with Chronic Hepatitis B
por: Winther, Thilde Nordmann, et al.
Publicado: (2013)

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients
por: Yang, Song, et al.
Publicado: (2016)

HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients
por: Song, Guangjun, et al.
Publicado: (2023)

Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B
por: Wi, Chung-Il, et al.
Publicado: (2016)

Using machine learning models to predict HBeAg seroconversion in CHB patients receiving pegylated interferon‐α monotherapy
por: Shang, Hongyan, et al.
Publicado: (2022)

The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore
por: Lacey, L F, et al.
Publicado: (2007)

Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro
por: Tacke, Frank, et al.
Publicado: (2012)

Correlations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-HBe Status in HBV Carriers
por: Lim, Chee Kent, et al.
Publicado: (2006)

Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis
por: Zhang, Zhan-qing, et al.
Publicado: (2019)

Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study
por: Zhang, Min, et al.
Publicado: (2020)

Analysis of clinical and virologic features in Hepatitis B e Antigen (HbeAg)-negative and HbeAg-positive Egyptian chronic hepatitis B patients
por: Fouad, Rabab, et al.
Publicado: (2020)

Effect of Adenine Arabinoside and α-Interferon in Patients with HBeAg-positive Chronic Active Hepatitis
por: Lee, Sang Uk, et al.
Publicado: (1990)

Manifestations of Perihepatic Lymph Nodes in Acute Flare of Chronic Hepatitis B: Association with HBeAg Status and with HBeAg Seroconversion
por: Ko, Yen-Ling, et al.
Publicado: (2015)

Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(+) or HBeAg(-): Epidemiological data from Shaanxi, China
por: Chen, Tianyan, et al.
Publicado: (2018)

Is the function of the HBeAg really unknown?
por: Milich, David R.
Publicado: (2019)

Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients
por: Zhao, Jing, et al.
Publicado: (2023)

Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon‐α treatment in HBeAg‐positive chronic hepatitis B patients
por: Zhu, Ming‐Yu, et al.
Publicado: (2018)

Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure
por: Weng, Min, et al.
Publicado: (2013)

A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a
por: Chen, Xinyue, et al.
Publicado: (2019)

Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study
por: Yang, Xiaoling, et al.
Publicado: (2017)

Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B: a multicentre, randomized controlled trial
por: Zheng, YongLi, et al.
Publicado: (2009)

Study on Post-Treatment Relapse in HBeAg Positive CHB Patients
por: Lu, Junfeng, et al.
Publicado: (2015)

Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver
por: Bae, Sung Kwan, et al.
Publicado: (2012)

Efficacy of pegylated interferon α2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy
por: Zhang, Xu-Qing, et al.
Publicado: (2013)

HBeAg-Negative/Anti-HBe-Positive Chronic Hepatitis B: A 40-Year-Old History
por: Bonino, Ferruccio, et al.
Publicado: (2022)

The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics
por: Kramvis, Anna
Publicado: (2016)

Characteristics of an Outpatient Cohort with HBeAg-Negative Chronic Hepatitis B
por: Dimzova, Marija, et al.
Publicado: (2019)

A cautionary note to hepatitis B e antigen (HBeAg)‐negative test results in pregnant women in an area prevalent of HBeAg‐negative chronic hepatitis B
por: Chalid, Maisuri T., et al.
Publicado: (2022)

Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients
por: Li, Minghui, et al.
Publicado: (2022)

Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
por: Song, Byung-Cheol, et al.
Publicado: (2014)

HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis
por: Xing, Tongjing, et al.
Publicado: (2017)

Effect of WSP, a Chinese Herbal Formula, on Th17/Treg Ratio and HBeAg Seroconversion in Telbivudine-Treated HBeAg-Positive Chronic Hepatitis B Patients with High Baseline ALT Levels (20–30 Times the ULN)
por: Zhang, Yang, et al.
Publicado: (2019)

Vitamin D-Binding protein Gene Polymorphism Predicts Pegylated Interferon-Related HBsAg Seroclearance in HBeAg-Negative Thai Chronic Hepatitis B Patients: A Multicentre Study
por: Thanapirom, Kessarin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gn8dt48jkkc3hf54ore5skdojc